// App-Quantinova.ai

P3-08-65 : PITX2 DNA methylation: A prognostic/predictive biomarker for anthracycline-based chemotherapy

Researchers

Presenter

  • Marion Kiechle

Principal Investigators

  • Gabriele Schricker

  • Rudolf Napieralski

  • Michaela Aubele

  • Gert Auer

  • Kurt Ulm

  • Jonathan Perkins

  • Stefan Paepke

  • Moritz Hamann

  • Olaf G. Wilhelm

Medical Centers

  • Klinik Gynäkologie und Geburtshilfe, Klinikum rechts der Isar, Technische Universität München, Comprehensive Cancer Center, Munich, Germany

  • Therawis Diagnostics GmbH, Munich, Germany

  • Therawis Pharma GmbH, Munich, Germany

  • Karolinska University Hospital, Stockholm, Sweden

  • Technische Universitat Munchen, Munich, Germany

  • QIAGEN Manchester, Manchester, United Kingdom

  • Klinik Gynäkologie und Geburtshilfe, Rotkreuzklinikum München, Munich, Germany

Locations

  • Germany

  • Sweden

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

  • Triple-negative breast cancer

Biomarkers

  • Pituitary homeobox 2

  • Progesterone receptor

  • Human epidermal growth factor receptor 2

  • DNA methylation

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved